NCT02663622 2024-01-23MK-7110-002Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 2 Completed44 enrolled 27 charts
NCT00003056 2021-05-06Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell TransplantationTakedaPhase 3 Terminated105 enrolled
NCT01379209 2019-10-23Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)Regimmune CorporationPhase 1/2 Completed68 enrolled
NCT00081055 2014-12-04OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic MalignanciesMesoblast, Ltd.Phase 2 Withdrawn
NCT00189488 2014-09-15Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) TransplantationSwedish Orphan BiovitrumPhase 2 Completed155 enrolled 19 charts